A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

The purpose of this Phase 3 study is to evaluate if BRd prolongs progression free survival (PFS) and/or improves minimal residual disease (MRD) negative status compared with DRd in participants with TI-NDMM.

Trial Details

NCT ID
NCT06679101
Phase
PHASE3
Sponsor
GlaxoSmithKline
Status
RECRUITING
Cancer Type
Newly Diagnosed Multiple Myeloma
Interventions
  • Belantamab mafodotin
  • Lenalidomide
  • Dexamethasone
  • Daratumumab
Locations (sample)
  • Mobile, Alabama, United States|30.69436,-88.04305
  • Phoenix, Arizona, United States|33.44838,-112.07404
  • Beverly Hills, California, United States|34.07362,-118.40036
  • Aurora, Colorado, United States|39.72943,-104.83192
  • Englewood, Florida, United States|26.96201,-82.3526

Key Eligibility Criteria

  • Is at least 18 or the legal age of consent in the jurisdiction in which the study is taking place, at the time of signing the informed consent.
  • Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form and…
  • NDMM with a requirement for treatment as documented per IMWG criteria.
  • Must have at least 1 aspect of measurable disease, as assessed by the central laboratory, defined as 1 of the following:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Newly Diagnosed Multiple Myeloma Trials on Trialify →